On April 11, the Vall d'Hebron Research Institute (VHIR) hosted a session on the use of Artificial Intelligence (AI) applied to the diagnosis of lung cancer within the framework of the PHASE IV AI project. During the day, health professionals and AI researchers met to evaluate the impact of technological assistance in various crucial aspects to improve workflows and promote rapid diagnosis. The Molecular Medical Imaging group of the VHIR, the Diagnostic Imaging Service and the Thoracic Radiology Section of the Vall d’Hebron University Hospital and the Digital Health and Multimedia Technologies Units of Eurecat collaborated in the organization of the event.

During the workshop, participants discussed the effects of AI on the accuracy and speed of diagnosis, as well as its influence on the workload of radiologists, the cost of procedures and clinical outcomes. Experts from both fields shared their knowledge and experiences, exploring innovative image-based ways to improve efficiency and support in lung cancer healthcare processes.

This event provided a unique opportunity to understand the major needs between two fields that have traditionally operated independently: medicine and AI. Collaboration between these sectors promises to drive significant advances in the field of digital health, with the potential to improve the quality of life of patients affected by lung cancer.

Participants highlight that these types of events are essential to strengthen existing collaborations and foster new alliances between health professionals and AI experts. It is hoped that the discussions and links established during this meeting will lead to the creation of innovative projects that will continue to improve the diagnosis and treatment of lung cancer in the future.

The session on lung cancer diagnosis was one of the first held in the PHASE IV AI project in the search for more effective and precise solutions for this and other diseases.

The PHASE IV AI project

The recently held session is part of the European project PHASE-IV-AI, which aims to advance the current system of data synthesis methods towards a more generalized approach to generating synthetic data and will develop metrics for use in trials clinical and validation. The advances will be validated in three real cases related to lung cancer, prostate cancer and ischemic stroke.

The PHASE IV AI is a project funded by the European Union’s Horizon Europe research and innovation program under grant agreement number 101095384 with a lifecycle of thirty-six months.